Shilpa Medicare’s arm partners with Swiss-based mAbTree Biologics for novel cancer therapy
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
CNBCTV187h
Shilpa Medicare arm partners with Switzerland-based mAbTree Biologics for new cancer drug
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
Innovent Is Said to Consider Licensing Partnership for Cancer Drug
Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing ...
MedPage Today on MSN1d
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian Cancer
Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
The American Journal of Managed Care5d
Biological Aging Linked to Colorectal Cancer Risk Regardless of Gender
Biological age, rather than chronological age, may be a stronger predictor of colorectal cancer risk—especially in older ...
Morningstar5d
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...
Progesterone Receptor Positive (PR+) Breast Cancer: Characteristics, Treatment and Prognosis
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday
Turnstone Biologics (NASDAQ:TSBX – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Turnstone Biologics to post ...